News headlines about Sucampo Pharmaceuticals (NASDAQ:SCMP) have trended positive on Saturday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sucampo Pharmaceuticals earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3809016241033 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Sucampo Pharmaceuticals remained flat at $$18.00 during midday trading on Friday, according to MarketBeat. 303,068 shares of the company’s stock were exchanged, compared to its average volume of 2,557,332. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $18.75. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.